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Background: Pathogenic intestinal protozoa infections are common in school-aged children in the developing
world and they are frequently associated with malabsorption syndromes and gastrointestinal morbidity. Since
diagnosis of these parasites is difficult, prevalence data on intestinal protozoa is scarce.
Methods: We collected two stool samples from school-aged children on Pemba Island, Tanzania, as part of a
randomized controlled trial before and 3 weeks after treatment with (i) single-dose albendazole (400 mg); (ii)
single-dose nitazoxanide (1,000 mg); (iii) nitazoxanide-albendazole combination (1,000 mg–400 mg), with each drug
given separately on two consecutive days; and (iv) placebo. Formalin-fixed stool samples were examined for the
presence of intestinal protozoa using an ether-concentration method to determine the prevalence and estimate
cure rates (CRs).
Results: Almost half (48.7%) of the children were diagnosed with at least one of the (potentially) pathogenic
protozoa Giardia intestinalis, Entamoeba histolytica/E. dispar and Blastocystis hominis. Observed CRs were high for all
treatment arms, including placebo. Nitazoxanide showed a significant effect compared to placebo against the
non-pathogenic protozoon Entamoeba coli.
Conclusions: Intestinal protozoa infections might be of substantial health relevance even in settings where they
are not considered as a health problem. Examination of a single stool sample with the ether-concentration method
lacks sensitivity for the diagnosis of intestinal protozoa, and hence, care is indicated when interpreting prevalence
estimates and treatment effects.
Keywords: Intestinal protozoa, Blastocystis hominis, Entamoeba histolytica/E. dispar, Giardia intestinalis, Albendazole,
Nitazoxanide, Ether-concentration methodBackground
Infection with pathogenic intestinal protozoa (e.g.
Entamoeba histolytica and Giardia intestinalis) result
in considerable gastrointestinal morbidity, malnutrition and
mortality worldwide, particularly among young children in
developing countries [1,2]. It has been estimated that* Correspondence: jennifer.keiser@unibas.ch
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reproduction in any medium, provided the orE. histolytica, the causative agent of amoebiasis, kills be-
tween 40,000 and 100,000 people each year; hence, is one
of the deadliest parasitic infections worldwide [2,3]. In the
People’s Republic of China alone, G. intestinalis affects an
estimated 28.5 million people every year [1]. The prevalence
of G. intestinalis has been estimated at 2–3% in the indus-
trialized world and 20–30% in developing countries [4].
Cryptosporidium spp. is another major causal agent of diar-
rhoea, primarily affecting immunocompromised individuals
such as those infected with HIV [3,5,6]. Blastocystis hominis
is a common additional anaerobic intestinal protozoon andLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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to clean water, sanitation and hygiene are strong drivers for
infection with intestinal protozoa [10-12].
Several drugs are currently available to treat intes-
tinal protozoa infections. Most commonly used are 5-
nitroimidazole compounds, including metronidazole,
tinidazole, ornidazole and secnidazole [13]. Alternative
effective agents, when given as multiple doses, include
nitazoxanide and albendazole [14-16].
Information on the prevalence of intestinal protozoa
infections is scarce and little data are available from sub-
Saharan Africa. For example, to the best of our knowledge,
the prevalence of intestinal protozoa infections on Pemba
Island has been assessed only twice and these investiga-
tions date back to 1984 and 1992 [17,18]. In the 1984 study,
the prevalence of G. intestinalis and E. histolytica among
children and adults combined were 5.6% and 3.1%, respec-
tively. Prevalences of 35.6%, 4.4%, 2.9%, 0.7% and 0.7% were
reported for Entamoeba coli, Endolimax nana, Chilomastix
mesnili, Entamoeba hartmanni and Iodamoeba bütschlii,
respectively (Figure 1) [17]. The study conducted in 1992
reported prevalences of 25.4% for E. histolytica and 6.6%
for G. intestinalis among children aged 9–17 years [18].
The study reported here was integrated in a randomized
controlled trial carried out in school-aged children on
Pemba Island, Tanzania in mid-2011 to asses the efficacy
and safety of single-dose nitazoxanide and albendazole
and a nitazoxanide-albendazole combination against
Trichuris trichiura and other soil-transmitted helminth
infections [19]. The aim of the present work was to eva-
luate the prevalence of intestinal protozoa infections in
these children and to determine whether the study drugs
had an effect on intestinal protozoa. Throughout the
study, the ether-concentration method was used on
formalin-fixed stool samples.Figure 1 Comparison of prevalence of intestinal protozoa infections asse
combined results (current study) against prevalence determined in 1984Methods
Ethics statement
Our randomized controlled trial was approved by the
ethics committee of Basel (EKBB; reference no. 225/10),
and the Ministry of Health and Social Welfare of
Zanzibar (ZAMREC; reference no. 0001/010) and is
registered at Current Controlled Trials (trial identifier:
ISRCTN08336605). Participating in the trial required
written informed consent from parents or legal guar-
dians and oral assent from children. Parents and
children were counseled that participation is voluntary
and withdrawal was possible at any time without spe-
cification of reasons and further obligations. At the
end of the trial, all children who were diagnosed with
soil-transmitted helminths received albendazole (single
oral dose of 400 mg).
Study area and design
Details of the study area, population and procedures have
been described previously [19]. In brief, the study was
carried out in June and July 2011 in children aged 7–15
years attending two schools (Wawi and Al-Sadik)
located within a radius of 10 km from Chake Chake,
the main city of Pemba Island. The study was a ran-
domized controlled trial with four treatment arms: (i)
single-dose albendazole (400 mg); (ii) single-dose nita-
zoxanide (1,000 mg); (iii) nitazoxanide-albendazole
combination (1,000 mg–400 mg) with each drug given
separately on two consecutive days; and (iv) placebo.
Of the 657 children, who completed the trial, 550
(83.7%) had formalin-fixed stool samples before and
after treatment and were therefore included in the
present study (treatment arms: (i) n = 136, (ii) n = 145,
(iii) n = 117, and (iv) n = 152; Wawi school: n = 404,
Al-Sadik school: n = 146).ssed in mid-2011 at baseline, 3 weeks post-treatment follow-up and
(study done by Pampiglione et al. [17]) on Pemba Island, Tanzania.
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Approximately 2 g of stool were fixed in 10 ml of 5%
formalin in Falcon tubes labeled with unique identifiers.
Stool samples were thoroughly broken down and homo-
genized with a wooden spatula. The formalin-fixed
samples were transferred to the Swiss Tropical and
Public Health Institute (Basel, Switzerland) and examined
within 10 months.
The fixed stool samples were processed with an ether-
concentration method [20,21]. Briefly, the homogenized
stool sample was filtered through a medical gauze into a
new tube and then centrifuged for 1 min at 500 g. The
supernatant was discarded. To the remaining pellet, 7 ml of
physiological NaCl-solution and 2–3 ml of diethyl ether
was added. Tubes were shaken and centrifuged again for 3
min at 500 g. The upper three layers were discarded. The
entire sediment was examined by experienced laboratory
technicians under a microscope for soil-transmitted hel-
minths at a magnification of 100×, and intestinal protozoa
at a magnification of 400× or 500× using oil immersion.
The current analysis focuses on intestinal protozoa,
including the pathogenic intestinal protozoa G. intestinalis
and E. histolytica/E. dispar (of note, these two Entamoeba
species cannot be differentiated by microscopy [22]); the
potentially pathogenic protozoon B. hominis, and the non-
pathogenic protozoa E. coli, E. hartmanni, E. nana, C. mes-
nili and I. bütschlii [7-9,23]. Cryptosporidium spp. was not
included, since it cannot easily be detected with the
formalin-ether concentration technique, and would have
required staining with the modified Ziehl-Neelsen method
[24]. Infection intensities were classified as follows: (i)
negative (no cysts or trophozoites in the entire sediment);
(ii) light (one to five cysts or trophozoites per slide); (iii)
moderate (one cyst or trophozoite per observation field at
the 400× or 500× magnification); and (iv) heavy (more
than one cyst or trophozoite per observation field) [21,25].
Statistical analysis
Data were double-entered into an Excel file (Microsoft
2010) and cross-checked. Statistical analysis was performed
using Stata version 10.1 (StataCorp; College Station, USA).
The prevalence of intestinal protozoa was determined
before treatment (baseline) and at the 3-week post-treat-
ment follow-up. Differences between prevalence at baseline
and follow-up were assessed using x2 test. In the baseline
prevalence analyses, the odds of being infected with a spe-
cific intestinal protozoon species for boys compared to girls
and for children from Wawi compared to Al-Sadik school
was calculated using logistic regression.
Cure rates (CRs) were estimated for each intestinal
protozoon species for the different treatment arms as
the percentage of positive children at baseline diagnosed
negative after treatment. Differences in CRs among treat-
ment arms were examined using logistic regressions.Reduction of infection intensity was assessed as the differ-
ence in infection intensities before and after treatment
among all individuals (negative individuals before treat-
ment were included in the analysis). Mean of differences in
infection intensities was calculated for each treatment arm
and for each intestinal protozoon species together with
95% confidence intervals (CIs). Decrease in infection inten-
sity was assumed as significant when 95% CI was below 0.
Results
Prevalence and intensity of intestinal protozoa infection
Based on the analysis of one formalin-fixed stool sample
per child at baseline, 74.7% of the children harboured at
least one intestinal protozoa species. About half of the
children (48.7%) were infected with at least one of the
three (potentially) pathogenic intestinal protozoa. The
prevalence of E. histolytica/E. dispar and G. intestinalis
was 18.0% and 16.4%, respectively before treatment
(Table 1). The potentially pathogenic intestinal protozoon
B. hominis was diagnosed in 28.0% of the children. Preva-
lences for the other intestinal protozoa were 51.5% for
E. coli, 19.5% for E. nana, 13.3% for E. hartmanni, 8.2% for
C. mesnili and 6.7% for I. bütschlii. For the pathogenic in-
testinal protozoon G. intestinalis, 44.4%, 38.9% and 16.7%
of the infections were classified as light, moderate and
heavy, respectively. The infection intensities of other intes-
tinal protozoa species are listed in Table 1.
Examination of the follow-up stool samples revealed the
following prevalences: 49.8% of children remained infected
with at least one of the three (potentially) pathogenic intes-
tinal protozoa and 69.3% of the children were found posi-
tive for at least one intestinal protozoa. The prevalence of
G. intestinalis, E. histolytica/E. dispar and B. hominis at the
3-week post-treatment follow-up was 17.3%, 16.4% and
31.1%, respectively (Figure 1). Prevalence for the non-
pathogenic intestinal protozoa species were 42.9% for
E. coli, 17.5% for E. nana, 12.9% for E. hartmanni, 8.2% for
I. bütschlii and 6.7% for C. mesnili. According to the x2 test,
only E. coli (p = 0.004) and all intestinal protozoa
combined (p = 0.046) showed significantly lower
prevalence at follow-up compared to baseline.
The odds of being infected with any intestinal protozoa
at baseline was significantly higher for girls than boys (odds
ratio (OR) = 1.97; 95% CI 1.32–2.93) (Table 2). There was a
trend (p <0.1) that girls were at a higher odds of being
infected with E. coli than boys (OR = 1.40; 95% CI 1.00–
1.96). Children from Wawi school had significantly lower
odds of being infected with B. hominis (OR = 0.64; 95% CI
0.43-0.97), E. nana (OR = 0.63; 95% CI 0.40–1.00) and
I. bütschlii (OR = 0.50; 95% CI 0.25–1.00) considering only
the baseline stool sample than children from Al-Sadik.
Additionally, there was a trend (p <0.1) that children from
Wawi school had a lower odds of being infected with
G. intestinalis (OR = 0.66; 95% CI 0.41–1.07) and any of
Table 1 Baseline characteristics of included school-aged children on Pemba Island in mid-2011 with regard to
intestinal protozoa infection
Characteristic, intestinal protozoa N (prevalence in %) Girls (%)/boys (%) Wawi (%)/Al-Sadik
school (%)low (%)/moderate (%)/heavy (%)
No. of children tested 550 271/279 404/146
G. intestinalis 90 (16.4) 37 (13.7)/53 (19.0) 59 (14.6)/31 (21.1)
40 (44.4)/35 (38.9)/15 (16.7)
E. histolytica/E. dispar 99 (18.0) 53 (19.6)/46 (16.5) 77 (19.1)/22 (15.1)
57 (57.6)/33 (33.3)/9 (9.1)
B. hominis 154 (28.0) 73 (26.9)/81 (29.0) 103 (34.9)/51 (25.5)
125 (81.2)/25 (16.2)/4 (2.6)
E. coli 283 (51.5) 151 (55.7)/132 (47.3) 210 (52.0)/73 (50.0)
101 (35.7)/104 (36.7)/78 (27.6)
E. nana 107 (19.5) 58 (21.4)/49 (17.6) 71 (17.6)/36 (24.7)
62 (57.9)/40 (37.4)/5 (4.7)
E. hartmanni 73 (13.3) 38 (14.0)/35 (12.0) 52 (12.9)/21 (14.4)
57 (78.1)/14 (19.2)/2 (2.7)
C. mesnili 45 (8.2) 27 (6.5)/18 (10.0) 31 (7.7)/14 (9.6)
21 (46.7)/18 (40.0)/6 (13.3)
I. bütschlii 37 (6.7) 18 (6.6)/19 (6.8) 22 (5.4)/15 (10.3)
31 (83.8)/5 (13.5)/1 (2.7)
G. intestinalis or E. histolytica/E. dispar or B. hominis 268 (48.7) 135 (49.8)/133 (47.8) 187 (46.3)/81 (55.5)
Any intestinal protozoa 411 (74.4) 219 (80.8)/192 (68.8) 297 (73.5)/114 (78.1)
Speich et al. Parasites & Vectors 2013, 6:3 Page 4 of 8
http://www.parasitesandvectors.com/content/6/1/3the three (potentially) pathogenic intestinal protozoa com-
bined (OR = 0.68; 95% CI 0.47–1.00).
Effect of antiparasitic treatment against intestinal
protozoa
Observed CRs were moderate to high for all intestinal
protozoa regardless of the treatments administeredTable 2 Odds ratios (OR) of being infected with intestinal
protozoa among school-aged children on Pemba Island
in mid-2011, as assessed by logistic regression
Intestinal protozoa OR girls vs.
boys (95% CI)
OR Wawi vs. Al-Sadik
school (95% CI)
G. intestinalis 0.67 (0.44–1.11) 0.66 (0.41–1.07)
E. histolytica/E. dispar 1.21 (0.78–1.87) 1.30 (0.77–2.19)
B. hominis 0.94 (0.64–1.37) 0.64 (0.43–0.97)*
E. coli 1.40 (1.00–1.96) 1.04 (0.71–1.53)
E. nana 1.34 (0.87–2.05) 0.63 (0.40–1.00)*
E. hartmanni 1.15 (0.70–1.89) 0.87 (0.50–1.50)
C. mesnili 1.65 (0.88–3.09) 0.74 (0.38–1.44)
I. bütschlii 1.04 (0.53–2.04) 0.50 (0.25–1.00)*
G. intestinalis or E. histolytica/
E. dispar or B. hominis
1.13 (0.81–1.58) 0.68 (0.47–1.00)
Any intestinal protozoa 1.97 (1.32–2.93)* 0.72 (0.46–1.14)
*p <0.05.
CI, confidence interval.(Table 3). The highest CR was observed for the
albendazole-nitazoxanide combination against E. nana
(CR 91.3%; 95% CI 78.8–100.0%). The lowest CR
among the antiparasitics tested was documented for
single-dose albendazole against E. coli (CR 33.3%; 95%
CI 22.4–44.3%). Note that the group of children
receiving placebo had moderate to high CRs against
intestinal protozoa infections. Comparing the out-
comes among treatment arms using logistic regression
revealed that single-dose nitazoxanide had a signifi-
cant effect on E. coli (OR = 0.35; 95% CI 0.18–0.68).
Furthermore, we observed a trend (p <0.1) with the
combination of nitazoxanide plus albendazole against
E. nana (OR = 0.18; 95% CI 0.02–1.27). All other
results of the logistic regressions revealed p-values
above 0.1; hence, there was no significant effect compared
to placebo.
Comparing the mean intensity of intestinal protozoa in-
fection before and 3 weeks after treatment in the different
arms revealed no significant effect for most of the assessed
intestinal protozoa (results not shown). The only signifi-
cant reductions of infection intensity (95% CI below 0)
were observed in the albendazole-nitazoxanide combin-
ation against E. histolytica/E. dispar (−0.21; 95% CI -0.34
to -0.09) and E. coli (−0.37; 95% CI -0.58 to -0.16) and in
the nitazoxanide single-dose treatment against E. coli in-
fection intensity (−0.37; 95% CI -0.58 to -0.16).
Table 3 Effect of albendazole, nitazoxanide, sequentially administered albendazole-nitazoxanide combination, and
placebo against intestinal protozoa infections among school-aged children on Pemba Island in mid-2011
Characteristic Single-dose
albendazole
Single-dose
nitazoxanide
Nitazoxanide-
albendazole combination
Placebo
G. intestinalis
No. of infected children 25 21 19 25
No. of children not cured after treatment 10 9 11 12
CR, % (95% CI) 60.0 57.1 42.1 52.0
(39.4–80.6) (34.1–80.2) (17.7–66.6) (31.0–73.0)
E. histolytica/E. dispar
No. of infected children 23 23 31 22
No. of children not cured after treatment 10 9 10 10
CR, % (95% CI) 56.5 60.9 67.7 54.5
(34.6–78.4) (39.3–82.4) (50.3–85.2) (31.9–77.1)
B. hominis
No. of infected children 35 37 33 49
No. of children not cured after treatment 15 16 10 16
CR, % (95% CI) 57.1 56.8 69.7 67.3
(39.9–74.4) (40.0–73.5) (53.1–86.2) (53.7–81.0)
E. coli
No. of infected children 75 82 56 70
No. of children not cured after treatment 50 38 27 50
CR, % (95% CI) 33.3 53.7 51.8 28.6
(22.4–44.3) (42.6–64.7) (38.3–65.3) (17.7–39.4)
E. hartmanni
No. of infected children 14 22 18 19
No. of children not cured after treatment 5 5 4 7
CR, % (95% CI) 64.3 77.3 77.8 63.2
(35.6–93.0) (58.3–96.3) (56.5–99.1) (39.3–87.0)
E. nana
No. of infected children 24 25 23 35
No. of children not cured after treatment 10 9 2 15
CR, % (95% CI) 58.3 64.0 91.3 57.1
(37.1–79.6) (43.8–84.2) (78.8–100.0) (39.9–74.4)
C. mesnili
No. of infected children 17 10 6 12
No. of children not cured after treatment 4 1 1 5
CR, % (95% CI) 76.5 90.0 83.3 58.3
(54.0–99.0) (67.4–100.0) (40.5–100.0) (25.6–91.1)
I. bütschlii
No. of infected children 5 13 8 11
No. of children not cured after treatment 1 2 2 4
CR, % (95% CI) 80.0 84.6 75.0 63.6
(24.5–100.0) (61.9–100.0) (36.3–100.0) (29.7–97.5)
CI, confidence interval; CR, cure rate.
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Since very little is known on the epidemiology of intestinal
protozoa in sub-Saharan Africa, we analyzed formalin-
fixed stool samples obtained from 550 school-aged chil-
dren who participated in a randomized controlled trial on
Pemba Island to assess the efficacy and safety of nitazoxa-
nide, albendazole and a combination of both drugs against
T. trichiura and other soil-transmitted helminths. This trial
found low CRs against soil-transmitted helminth species
[19]. Importantly, the study provided an opportunity to
shed new light on the extent of intestinal protozoa infec-
tions in a child cohort and to determine whether the differ-
ent study treatments had an effect on intestinal
protozoa species.
Our results confirm that intestinal protozoa are a pub-
lic health issue on Pemba Island. Indeed, almost half of
the children were infected with at least one of the
three (potentially) pathogenic intestinal protozoa.
When considering the results from the baseline and
the 3-week post-treatment follow-up, assuming that a
child who was diagnosed positive at follow-up was
diagnosed as a false-negative case at baseline, the
prevalence of intestinal protozoa infection was even
higher (Figure 1). This issue is most likely explained
by the lack of sensitivity when examining only a single
stool sample with the ether-concentration technique, an
important limitation of our study. Hence, in future stud-
ies, multiple stool samples should be examined and sub-
jected to the ether-concentration method or more
sensitive molecular approaches employed to improve
diagnostic accuracy [26,27].
A recent study reported only moderate sensitivity for
the ether-concentration technique compared to the
FLOTAC technique when examining the same formalin-
fixed stool samples [28]. However, a study among five
European reference laboratories showed that the agree-
ment of diagnostic results was only moderate for patho-
genic intestinal protozoa although the participating
centres adhered to the same standard operating proce-
dures for the ether-concentration technique [21]. In par-
ticular, E. histolytica is frequently misdiagnosed, even by
experienced laboratory personnel [29].
We found that girls were generally at higher odds of an
infection with any of the intestinal protozoa encountered
than boys. Similar results were found by Mohammed
Mahady and colleagues in Malaysia [30]. On the other
hand, Traoré et al., in a study carried out in school-aged
children in Côte d’Ivoire, reported a considerably higher
prevalence of intestinal protozoa among boys than girls
[31], corroborating findings by Cifuentes et al. from
Mexico, where boys were at higher odds of a G. intestinalis
infection that girls [32]. Other studies found no gender dif-
ference at all [33]. These findings indicate that intestinal
protozoa infections may be related to gender-specificbehaviour within a community. In addition, we observed
statistically significant differences for some of the intestinal
protozoa between the two schools. Hence, even
though the schools are located only a few kilometers
apart and the two settings were quite similar, at least
in terms of socioeconomic status, availability of safe
water supply and sanitation infrastructure, different
infection profiles were observed. This highlights the
possibility of ‘micro-geographic’ variability in ende-
micity of intestinal protozoa infection. One explanation
could be that Al-Sadik school is located close to an orph-
anage, where transmission of intestinal protozoa might be
enhanced. Other behavioural, infrastructure or environ-
mental factors that may account for our observation should
be investigated in future studies.
Intestinal protozoa often co-occur with intestinal
nematodes and it is therefore important to determine
whether anthelminthic and other antiparasitic drugs
have an effect on concomitant intestinal protozoa infec-
tions. Albendazole, for example, was found in a recent
meta-analysis to be as effective as metronidazole against
G. intestinalis [34]. The observed CRs against all intes-
tinal protozoa were moderate to high in the three treat-
ment groups. However – and contrary to what we
expected – there was also a moderate treatment efficacy
in the placebo group, which is difficult to explain other
than a diagnostic dilemma. Our findings therefore have
to be interpreted with caution. The high ‘cure rate’
observed within the placebo group underscores that ana-
lysis of a single stool sample with the formalin-ether
concentration technique is unreliable, and hence, the
CRs for the three treatment schemes investigated here
are likely overestimated. Still, our results show that none
of the drugs administered as single dose resulted in cure
of all infected children. Only moderate CRs were
observed against G. intestinalis, E. histolytica/E. dispar
and the potentially pathogenic B. hominis. A further
limitation is the relatively small number of positive
children for specific intestinal protozoa. Infection in-
tensity did not significantly decrease after treatment
with the exception of E. coli in the nitazoxanide
group. Note that intestinal protozoa multiply within
the host, which can also influence infection intensity
results [35]. Further, the incubation time for different
intestinal protozoa is between 7 and 28 days, meaning
that it is possible that within the 3-week period
before and after treatment, re-infection had occured
[36-40]. The clinical relevance of the moderate CRs
suggests that single-dose albendazole or nitazoxanide
or a combination of the two drugs do not have suffi-
cient efficacy against pathogenic intestinal protozoa.
However, multiple stool samples should be examined
to strengthen the diagnostic accuracy for these
infections.
Speich et al. Parasites & Vectors 2013, 6:3 Page 7 of 8
http://www.parasitesandvectors.com/content/6/1/3Conclusion
Our study revealed that intestinal protozoa infections
are highly prevalent among school-aged children on
Pemba Island, a setting where these intestinal protozoa
were not considered of major importance thus far. The
difficulty in accurately diagnosing intestinal protozoa
infections, also experienced in our study, might be one
of the chief reasons why these pathogens and the
diseases they cause are often neglected, even in settings
where mass treatment are underway against intestinal
helminth infections [21]. The prevalence of intestinal
protozoa is therefore unknown in many settings and
consequently the disease burden cannot be fully quanti-
fied [41]. Accurate diagnostic tools that can be applied
at the point-of-care are thus urgently required. Finally,
drugs and effective treatment regimens for intestinal
protozoa infections to be used in public health campaigns
are still far out of reach.
Competing interests
None of the authors has any conflict of interest concerning the work
reported in this paper.
Authors’ contributions
BS, ShMA, SaMA, JU, MA and JK designed the study; BS, HM, ShMA, SaMA,
and JK implemented the study; BS managed the data; BS, HM, IIB, JU and JK
analyzed and interpreted the data; BS wrote the first draft of the paper; HM,
ShMA, SaMA, IIB, JU, MA and JK revised the manuscript. All authors read, and
approved the manuscript prior to submission and assisted with the final
revision of the manuscript.
Author details
1Department of Medical Parasitology and Infection Biology, Swiss Tropical
and Public Health Institute, P.O. Box, CH-4002 Basel, Switzerland. 2University
of Basel, P.O. Box, CH-4003 Basel, Switzerland. 3Department of Medical and
Diagnostic Services, Swiss Tropical and Public Health Institute, P.O. Box,
CH-4002 Basel, Switzerland. 4Public Health Laboratory (Pemba)-Ivo de Carneri,
P.O. Box, TZ-122 Wawi, Chake Chake, Tanzania. 5Divisions of Internal
Medicine and Infectious Diseases, Toronto General Hospital, Toronto, Ontario,
Canada. 6Department of Epidemiology and Public Health, Swiss Tropical and
Public Health Institute, P.O. Box, CH-4002 Basel, Switzerland. 7Ivo de Carneri
Foundation, P.O. Box, IT-10122 Milan, Italy.
Received: 13 December 2012 Accepted: 25 December 2012
Published: 4 January 2013
References
1. Feng Y, Xiao L: Zoonotic potential and molecular epidemiology of Giardia
species and giardiasis. Clin Microbiol Rev 2011, 24:110–140.
2. Stanley SL: Amoebiasis. Lancet 2003, 361:1025–1034.
3. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J,
Adair T, Aggarwal R, Ahn SY, et al: Global and regional mortality from 235
causes of death for 20 age groups in 1990 and 2010: a systematic
analysis for the Global Burden of Disease Study 2010. Lancet 2012,
380:2095–2128.
4. Escobedo AA, Cimerman S: Giardiasis: a pharmacotherapy review. Expert
Opin Pharmacother 2007, 8:1885–1902.
5. Jex AR, Smith HV, Nolan MJ, Campbell BE, Young ND, Cantacessi C, Gasser
RB: Cryptic parasite revealed improved prospects for treatment and
control of human cryptosporidiosis through advanced technologies. Adv
Parasitol 2011, 77:141–173.
6. Davies AP, Chalmers RM: Cryptosporidiosis. BMJ 2009, 339:b4168.
7. Stensvold CR, Lewis HC, Hammerum AM, Porsbo LJ, Nielsen SS, Olsen KE,
Arendrup MC, Nielsen HV, Mølbak K: Blastocystis: unravelling potential risk
factors and clinical significance of a common but neglected parasite.
Epidemiol Infect 2009, 137:1655–1663.8. Leder K, Hellard ME, Sinclair MI, Fairley CK, Wolfe R: No correlation between
clinical symptoms and Blastocystis hominis in immunocompetent
individuals. J Gastroenterol Hepatol 2005, 20:1390–1394.
9. Sheehan DJ, Raucher BG, McKitrick JC: Association of Blastocystis hominis
with signs and symptoms of human disease. J Clin Microbiol 1986,
24:548–550.
10. Yoder JS, Harral C, Beach MJ: Giardiasis surveillance-United States, 2006–
2008. MMWR Surveill Summ 2010, 59:15–25.
11. Hellard ME, Sinclair MI, Hogg GG, Fairley CK: Prevalence of enteric
pathogens among community based asymptomatic individuals.
J Gastroenterol Hepatol 2000, 15:290–293.
12. Taylor DN, Houston R, Shlim DR, Bhaibulaya M, Ungar BL, Echeverria P:
Etiology of diarrhea among travelers and foreign residents in Nepal.
JAMA 1988, 260:1245–1248.
13. Escobedo AA, Almirall P, Alfonso M, Cimerman S, Rey S, Terry SL: Treatment
of intestinal protozoan infections in children. Arch Dis Child 2009,
94:478–482.
14. Rodriguez-Garcia R, Rodriguez-Guzman LM, Cruz del Castillo AH:
Effectiveness and safety of mebendazole compared to nitazoxanide in
the treatment of Giardia lamblia in children. Rev Gastroenterol Mex 1999,
64:122–126.
15. Yereli K, Balcioglu IC, Ertan P, Limoncu E, Onag A: Albendazole as an
alternative therapeutic agent for childhood giardiasis in Turkey. Clin
Microbiol Infect 2004, 10:527–529.
16. Ortiz JJ, Ayoub A, Gargala G, Chegne NL, Favennec L: Randomized clinical
study of nitazoxanide compared to metronidazole in the treatment of
symptomatic giardiasis in children from northern Peru. Aliment
Pharmacol Ther 2001, 15:1409–1415.
17. Pampiglione S, Visconti S, Stefanini A: Human intestinal parasites in sub-
Saharan Africa. III. Pemba Island (Zanzibar-Tanzania). Parassitologia 1987,
29:27–35 (in Italian).
18. Albonico M, De Carneri I, Di Matteo L, Ghiglietti R, Toscano P, Uledi MK,
Savioli L: Intestinal parasitic infections of urban and rural children on
Pemba Island: implications for control. Ann Trop Med Parasitol 1993,
87:579–583.
19. Speich B, Ame SM, Ali SM, Alles R, Hattendorf J, Utzinger J, Albonico M,
Keiser J: Efficacy and safety of nitazoxanide, albendazole, and
nitazoxanide-albendazole against Trichuris trichiura infection: a
randomized controlled trial. PLoS Negl Trop Dis 2012, 6:e1685.
20. Marti H, Escher E: SAF-an alternative fixation solution for parasitological
stool specimens. Schweiz Med Wochenschr 1990, 120:1473–1476 (in
German).
21. Utzinger J, Botero-Kleiven S, Castelli F, Chiodini PL, Edwards H, Kohler N,
Gulletta M, Lebbad M, Manser M, Matthys B, et al: Microscopic diagnosis of
sodium acetate-acetic acid-formalin-fixed stool samples for helminths
and intestinal protozoa: a comparison among European reference
laboratories. Clin Microbiol Infect 2010, 16:267–273.
22. Diamond LS, Clark CG: A redescription of Entamoeba histolytica
Schaudinn, 1903 (Emended Walker, 1911) separating it from Entamoeba
dispar Brumpt, 1925. J Eukaryot Microbiol 1993, 40:340–344.
23. Pierce KK, Kirkpatrick BD: Update on human infections caused by
intestinal protozoa. Curr Opin Gastroenterol 2009, 25:12–17.
24. Leitch GJ, He Q: Cryptosporidiosis-an overview. J Biomed Res 2012,
25:1–16.
25. Coulibaly JT, Fürst T, Silué KD, Knopp S, Hauri D, Ouattara M, Utzinger J,
N’Goran EK: Intestinal parasitic infections in schoolchildren in different
settings of Côte d’Ivoire: effect of diagnostic approach and implications
for control. Parasit Vectors 2012, 5:135.
26. Marti H, Koella JC: Multiple stool examinations for ova and parasites and
rate of false-negative results. J Clin Microbiol 1993, 31:3044–3045.
27. van Lieshout L, Verweij JJ: Newer diagnostic approaches to intestinal
protozoa. Curr Opin Infect Dis 2010, 23:488–493.
28. Becker SL, Lohourignon LK, Speich B, Rinaldi L, Knopp S, N’Goran EK,
Cringoli G, Utzinger J: Comparison of the Flotac-400 dual technique and
the formalin-ether concentration technique for diagnosis of human
intestinal protozoon infection. J Clin Microbiol 2011, 49:2183–2190.
29. Rayan HZE: Microscopic overdiagnosis of intestinal amoebiasis. J Egypt
Soc Parasitol 2005, 35:941–951.
30. Mohammed Mahdy AK, Surin J, Wan KL, Mohd-Adnan A, Hesham Al-
Mekhlafi MS, Lim YAL: Giardia intestinalis genotypes: risk factors and
correlation with clinical symptoms. Acta Trop 2009, 112:67–70.
Speich et al. Parasites & Vectors 2013, 6:3 Page 8 of 8
http://www.parasitesandvectors.com/content/6/1/331. Traoré SG, Odermatt P, Bonfoh B, Utzinger J, Aka ND, Adoubryn KD,
Assoumou A, Dreyfuss G, Koussémon M: No Paragonimus in high-risk
groups in Côte d'Ivoire, but considerable prevalence of helminths and
intestinal protozoon infections. Parasit Vectors 2011, 4:96.
32. Cifuentes E, Suarez L, Espinosa M, Juarez-Figueroa L, Martinez-Palomo A:
Risk of Giardia intestinalis infection in children from an artificially
recharged groundwater area in Mexico City. Am J Trop Med Hyg 2004,
71:65–70.
33. Prado MS, Strina A, Barreto ML, Oliveira-Assis AM, Paz LM, Cairncross S: Risk
factors for infection with Giardia duodenalis in pre-school children in the
city of Salvador, Brazil. Epidemiol Infect 2003, 131:899–906.
34. Solaymani-Mohammadi S, Genkinger JM, Loffredo CA, Singer SM: A meta-
analysis of the effectiveness of albendazole compared with
metronidazole as treatments for infections with Giardia duodenalis. PLoS
Negl Trop Dis 2010, 4:e682.
35. Wright SG: Protozoan infections of the gastrointestinal tract. Infect Dis Clin
North Am 2012, 26:323–339.
36. Rendtorff RC: The experimental transmission of human intestinal
protozoan parasites. II. Giardia lamblia cysts given in capsules. Am J Hyg
1954, 59:209–220.
37. Rendtorff RC, Holt CJ: The experimental transmission of human intestinal
protozoan parasites. IV. Attempts to transmit Endamoeba coli and
Giardia lamblia cysts by water. Am J Hyg 1954, 60:327–338.
38. Jokipii AM, Hemilä M, Jokipii L: Prospective study of acquisition of
Cryptosporidium, Giardia lamblia, and gastrointestinal illness. Lancet 1985,
326:487–489.
39. Katz M, Despammier DD, Gwadz RW: Parasitic Diseases. New York, N.Y:
Springer; 1989.
40. Garcia LS, Bruckner DA: Diagnostic Medical Parasitology. 3rd edition.
Washington, D.C.: ASM Press; 1997.
41. Okhuysen PC: Traveler’s diarrhea due to intestinal protozoa. Clin Infect Dis
2001, 33:110–114.
doi:10.1186/1756-3305-6-3
Cite this article as: Speich et al.: Prevalence of intestinal protozoa
infection among school-aged children on Pemba Island, Tanzania, and
effect of single-dose albendazole, nitazoxanide and albendazole-
nitazoxanide. Parasites & Vectors 2013 6:3.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
